Sui Ankui, Zhang Xifeng, Zhu Qing
Department of Oncology, Jimo Hospital of Traditional Chinese Medicine, Qingdao, Shandong 266200, P.R. China.
Department of Infectious Disease, The People's Hospital of Jimo District, Qingdao, Shandong 266200, P.R. China.
Oncol Lett. 2019 Mar;17(3):3247-3252. doi: 10.3892/ol.2019.9958. Epub 2019 Jan 23.
Diagnostic value of microRNA (miR)-197 and miR-145 in non-small cell lung cancer (NSCLC) and their relationship with the clinicopathological parameters of NSCLC patients were investigated. Seventy-six patients with NSCLC admitted to Jimo Hospital of Traditional Chinese Medicine from July 2016 to March 2018 were enrolled in group A, while 60 healthy who received health examinations during the same period were enrolled in group B. The relative expression levels of serum miR-197 and miR-145 were detected by RT-qPCR. The relative expression of serum miR-197 in group A was significantly higher than that in group B (P<0.001); the relative expression of serum miR-145 in group A was significantly lower than that in group B (P<0.001); serum miR-197 in group A showed association with the clinical stage of NSCLC patients (P<0.001); serum miR-145 in group A was associated with the clinical stage and pathological differentiation of patients with NSCLC (P<0.001). The AUC of serum miR-197 diagnosis of NSCLC was 0.864 (95% CI: 0.804-0.924), with a diagnostic sensitivity of 73.68% and a specificity of 85.00%; the AUC of serum miR-145 diagnosis of NSCLC was 0.879 (95% CI: 0.824-0.934), with a diagnostic sensitivity of 84.21% and a specificity of 71.67%; the AUC of the diagnosis of the combination of serum miR-197 and miR-145 for NSCLC was 0.952 (95% CI: 0.919-0.984), with a diagnostic sensitivity of 92.10% and a specificity of 78.33%. miR-197 and miR-145 are potential new biomarkers in the diagnosis of NSCLC due to their possible involvement in the occurrence and development of NSCLC. With good sensitivity and specificity of single miR-197 and single miR-145 for the diagnosis of NSCLC, the combined detection of miR-197 and miR-145 can achieve a better sensitivity in the diagnosis of NSCLC.
研究了微小RNA（miR）-197和miR-145在非小细胞肺癌（NSCLC）中的诊断价值及其与NSCLC患者临床病理参数的关系。将2016年7月至2018年3月在即墨市中医医院收治的76例NSCLC患者纳入A组，同期60例接受健康体检的健康者纳入B组。采用RT-qPCR检测血清miR-197和miR-145的相对表达水平。A组血清miR-197的相对表达水平显著高于B组（P<0.001）；A组血清miR-145的相对表达水平显著低于B组（P<0.001）；A组血清miR-197与NSCLC患者的临床分期相关（P<0.001）；A组血清miR-145与NSCLC患者的临床分期及病理分化相关（P<0.001）。血清miR-197诊断NSCLC的AUC为0.864（95%CI：0.804-0.924），诊断敏感性为73.68%，特异性为85.00%；血清miR-145诊断NSCLC的AUC为0.879（95%CI：0.824-0.934），诊断敏感性为84.21%，特异性为71.67%；血清miR-197和miR-145联合诊断NSCLC的AUC为0.952（95%CI：0.919-0.984），诊断敏感性为92.10%，特异性为78.33%。miR-197和miR-145可能参与NSCLC的发生发展，是NSCLC诊断中有潜力的新型生物标志物。单miR-197和单miR-145对NSCLC诊断具有良好的敏感性和特异性，miR-197和miR-145联合检测在NSCLC诊断中可获得更好的敏感性。
